Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Retained Earnings: 2011-2024

Historic Retained Earnings for RedHill Biopharma (RDHL) over the last 14 years, with Dec 2024 value amounting to -$414.8 million.

  • RedHill Biopharma's Retained Earnings fell 1.97% to -$418.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$418.1 million, marking a year-over-year decrease of 1.97%. This contributed to the annual value of -$414.8 million for FY2024, which is 1.73% down from last year.
  • Per RedHill Biopharma's latest filing, its Retained Earnings stood at -$414.8 million for FY2024, which was down 1.73% from -$407.7 million recorded in FY2023.
  • RedHill Biopharma's Retained Earnings' 5-year high stood at -$280.3 million during FY2020, with a 5-year trough of -$433.9 million in FY2022.
  • Its 3-year average for Retained Earnings is -$418.8 million, with a median of -$414.8 million in 2024.
  • Per our database at Business Quant, RedHill Biopharma's Retained Earnings tumbled by 34.54% in 2020 and then grew by 6.02% in 2023.
  • RedHill Biopharma's Retained Earnings (Yearly) stood at -$280.3 million in 2020, then plummeted by 31.22% to -$367.9 million in 2021, then declined by 17.94% to -$433.9 million in 2022, then increased by 6.02% to -$407.7 million in 2023, then declined by 1.73% to -$414.8 million in 2024.